| UniProt/SwissProt ID: | COF2_HUMAN |
| Description: | cofilin 2 (muscle) [Source:HGNC Symbol;Acc:1875] |
| Location: | chr14 q13.1 |
| Node attribute: | substrate |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| T88 | ALYDAtYETKE | Cofilin_ADF | PhosphoSitePlus |
| S3 | MASGVtVN | RegPhos; SysPTM | |
| Y85 | CRYALyDATYE | HPRD | |
| S3 | ___MAsGVTVN | PhosphoSitePlus; SysPTM | |
| S23 | MKVRKsSTQEE | Cofilin_ADF | PhosphoSitePlus |
| S3 | VTVN | LIMK1 | HPRD; phosphoELM; SysPTM |
| Y85 | CRYALyDATYE | Cofilin_ADF | PhosphoSitePlus |
| S94 | YETKEsKKEDL | Cofilin_ADF | PhosphoSitePlus |
| Y89 | LYDATyETKES | Cofilin_ADF | PhosphoSitePlus |
| S24 | KVRKSsTQEEI | CaMK2_group | RegPhos |
| S24 | KVRKSsTQEEI | CaM-KII_group | phosphoELM |
| Y89 | LYDATyETKES | HPRD; RegPhos | |
| Y117 | KSKMIyASSKD | Cofilin_ADF | PhosphoSitePlus |
| T91 | DATYEtKESKK | Cofilin_ADF | PhosphoSitePlus |
| S3 | VTVN | phosphoELM; SysPTM | |
| Y68 | TVEDPyTSFVK | Cofilin_ADF | PhosphoSitePlus |
| S24 | KVRKSsTQEEI | RegPhos | |
| S3 | MASGVtVN | LIMK1 | RegPhos; SysPTM |
| Y82 | LNDCRyALYDA | Cofilin_ADF | PhosphoSitePlus |
| Dephosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| S3 | sGVTVNDE | SSH1 | HPRD |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000340635 | I47M | Sjoblom2006, COSMIC, HPI | Breast Cancer | 16959974, 18428421 | ENSP00000298159 | I47M | Sjoblom2006, HPI, BIOMART | Breast Cancer | 16959974, 18428421, 21930507, 21930502 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000298159 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 3.1 | 15759316 | ENSP00000298159 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.77 | 18973835 | ENSP00000298159 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.67 | 18973835 | ENSP00000298159 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.77 | 19714814 | ENSP00000298159 | Uterine Cancer | Cancer vs. Cancer | cell line | Down | 17616526 |
| Hyperphosphorylation site |
| COF2_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| TNI3K_HUMAN | COF2_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| ZAGL2_HUMAN | COF2_HUMAN | kinase -> substrate | RegPhos |
| LIMK1_HUMAN | COF2_HUMAN | kinase -> substrate | HPRD; RegPhos |
| KCC4_HUMAN | COF2_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| SSH1_HUMAN | COF2_HUMAN | phosphatase -> substrate | HPRD |
| Function Annotation |
| KEGG Pathway |
| KEGG ID | Pathway |
|---|---|
| hsa05133 | Pertussis |
| hsa04360 | Axon guidance |
| hsa04810 | Regulation of actin cytoskeleton |
| hsa04666 | Fc gamma R-mediated phagocytosis |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0005515 | protein binding | IPI | molecular_function |
| GO:0003779 | actin binding | IEA | molecular_function |
| GO:0005856 | cytoskeleton | IEA | cellular_component |
| GO:0005737 | cytoplasm | IEA | cellular_component |
| GO:0005622 | intracellular | IEA | cellular_component |
| GO:0016363 | nuclear matrix | IEA | cellular_component |